Google Translate
Changjiang Daily - Reports from Huazhong University of Science and Technology, Huazhong University of Science and Technology Tongji Medical College, Huazhong University of Science and Technology Tongji Medical College affiliated Wuhan Children's Hospital scholars jointly Xi'an Jiaotong University First Affiliated Hospital, Chinese Academy of Sciences Beijing Genomics Research Institute, Huawei Cloud Research Team announced that,
Five antiviral drugs that may be effective for the new coronavirus (2019-nCoV) were screened.
It is reported that the above-mentioned joint scientific research team for the 2019 new coronavirus of a number of target proteins (of which Mpro protein crystal structure provided by the Chinese Academy of Sciences Raoko and academician team), 8506 drugs on the market or in the ongoing clinical trials in the ultra-large-scale computer-aided drug screening work, and achieved the first phase in a week.
The study found that five drugs may be effective for the 2019 new coronavirus:
Beclabuvir, Saquinavir, Bictegravir, Lopinavir and Dolutegravir
The joint team found that Beclabuvir not only binds to the Mpro protein, but may also be a potential inhibitor of the RNA polymerase NSP12 of the 2019 new coronavirus RNA dependence, and saquinavir not only binds well to the Mpro protein. It can also be combined with the S protein of the 2019 new coronavirus, which can prevent the virus from amplifying both inside the cell and on the surface.
It is understood that at present, the joint scientific research team is on the above five antiviral drugs for cytological verification, and promote clinical trials of drugs. The research results released by the joint research team will be open to biomedical research institutions through Huawei Cloud for antiviral drug research and development.
除了李兰娟团队成果 武汉还有好消息:5种药物可能有效
2020年02月04日 23:53:57
来源:
长江日报
806人参与71评论
长江日报-长江网记者4日从
华中科技大学获悉,2月3日,华中科技大学同济医学院、华中科技大学同济医学院附属武汉儿童医院学者联合西安交通大学第一附属医院、中科院北京基因组研究所、华为云科研团队宣布,
筛选出五种可能对2019新型冠状病毒(2019-nCoV)有效的抗病毒药物。
据悉,上述联合科研团队针对2019新型冠状病毒的多个靶标蛋白(其中Mpro 蛋白晶体结构由中科院饶子和院士团队提供),对8506种上市或者正在进行临床试验的药物中进行超大规模计算机辅助药物筛选工作,并在一周内取得了第一阶段成果。
研究发现,有五种药物可能对2019新型冠状病毒有效,分别是
Beclabuvir,沙奎那韦(Saquinavir),比特拉韦(Bictegravir),洛匹那韦(Lopinavir),多替拉韦(Dolutegravir) 。
联合科研团队发现,Beclabuvir不仅可以和Mpro蛋白结合,还可能是2019新型冠状病毒RNA依赖的RNA聚合酶NSP12的一种潜在抑制剂;沙奎那韦(Saquinavir)不仅可以很好地同Mpro蛋白结合,还能够和2019新型冠状病毒的S蛋白相结合,可以同时在细胞内部和表面阻止病毒的扩增。
据了解,目前,联合科研团队正在对上述五种抗病毒药物进行细胞学验证,并推动药物临床实验。本次联合科研团队发布的研究成果都将通过华为云面向生物医药研究机构开放,用于抗病毒药物研发。
Another news on two drugs deemed to be more effective after research results, these 2 drugs will replace current ones used for Coronavirus treatments.
Major achievements of Li Lanxuan's team: Abidore and Dalunawe can effectively suppress coronaviruses
Tuesday, February 4, 2020 5:23:15 PM
Changjiang Daily - Changjiang Daily - Changjiang Network February 4 (Reporter Huang Qi) 4, the Chinese Academy of Engineering, the National Health and Health Commission high-level expert group member Li Lanxuan team, in Wuhan
announced the treatment of new coronary virus infection pneumonia latest research results.
According to preliminary tests, in vitro cell experiments showed:
(1)
Abigail at 10 to 30 micromolar concentration, compared with the drug untreated control group, can effectively inhibit coronavirus up to 60 times, and significantly inhibit the virus on the cell lesions effect.
(2)
Dalunavir at a concentration of 300 micromoles, can significantly inhibit viral replication, compared with the unused drug treatment group, inhibition efficiency of 280 times.
Li Lanxuan said that the anti-AIDS drug Crech on the treatment of new coronary virus infection pneumonia effect is not good, and toxic side effects. She recommended that the two drugs be included in the National Health and Reform Commission's Pneumonia Treatment Programme for New Coronary Virus Infections (Trial Sixth Edition).
Li Lanxuan academician team members, Zhejiang Aid E'o intensive care team leader, Zhejiang University, the first hospital vice president Chen Zubing reminded, "These two drugs are prescription drugs, patients must be under the guidance of the doctor to take." He also said that the two drugs are now used in patients with pneumonia with the new coronavirus infection in Zhejiang Province, and the next step is to replace other less effective drugs with these drugs.
李兰娟院士团队重大成果:阿比朵尔、达芦那韦能有效抑制冠状病毒
2020年02月04日 17:23:15
长江日报-长江网2月4日讯(记者黄琪)4日,中国工程院院士、国家卫健委高级别专家组成员李兰娟团队,在武汉公布治疗新型冠状病毒感染的肺炎的最新研究成果。
李兰娟院士说,根据初步测试,在体外细胞实验中显示:(1)阿比朵尔在10~30微摩尔浓度下,与药物未处理的对照组比较,能有效抑制冠状病毒达到60倍,并且显著抑制病毒对细胞的病变效应。(2)达芦那韦在300微摩尔浓度下,能显著抑制病毒复制,与未用药物处理组比较,抑制效率达280倍。
李兰娟院士说,抗艾滋病药物克力芝对治疗新型冠状病毒感染的肺炎效果不佳,且有毒副作用。她建议将以上两种药物列入国家卫健委《新型冠状病毒感染的肺炎诊疗方案(试行第六版)》。
李兰娟院士团队成员、浙江援鄂重症救治组领队、浙大一院副院长陈作兵提醒,“这两种药为处方药,患者一定要在医生的指导下服用。”他还介绍,现在这两种药物已经在浙江省新型冠状病毒感染的肺炎患者中使用,下一步计划用这两种药物替代其他效果欠佳的药物。